NGC-Iri
PCS11T Small Molecule Target: SN38
- Undisclosed indication
Processa Pharmaceuticals
Most recent annual filing: 2026-03-15
- Preferred Stock Conversion Proposal corporate4Q 2026Preferred Stock Conversion Proposal corporate, 4Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
PCS12852
Small Molecule Target: 5HT4
PCS499
VT-7208
Small Molecule Target: BTK
Discontinued (1)
- NGC-Cap — Breast Cancer · License agreement with Elion terminated; PCS6422 program returned to Elion; Phase 2 trial in advanced/metastatic breast cancer being closed
Biotech Distilled coverage (3)
- 2026-07-29 UPDATE: Processa Pharmaceuticals (PCSA) - The Shell Gets a Real Drug 🔒 Paid
- 2026-05-08 UPDATE: Processa Pharmaceuticals (PCSA) - The Cash Crash and the Crypto Doubling-Down 🔒 Paid
- 2026-04-11 Processa Pharmaceuticals (PCSA) - Scientific Deep Dive for PCS6422 and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.